Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 70/100

Altimmune to Participate at Two Upcoming Investor Conferences

Wednesday, May 14, 2025 1 min read
Key Takeaway: Altimmune, Inc. is set to participate in two upcoming investor conferences: the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, and the Jefferies Global Healthcare Conference on June 4, 2025. The company's management team will be available for one-on-one meetings, enhancing investor engagement. Altimmune focuses on developing peptide-based therapeutics for liver and cardiometabolic diseases, with its lead program, pemvidutide, addressing multiple health conditions. The sessions will be accessible via live webcast on Altimmune's website.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in multiple high-profile investor conferences
  • Opportunity for 1x1 meetings with management team
  • Increased visibility for Altimmune's novel peptide-based therapeutics
  • Focus on significant medical needs such as obesity and liver diseases

Full Press Release Details

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, NY)
Tuesday, May 20, 2025
Fireside Chat at 10:00 a.m. Eastern Time
Jefferies Global Healthcare Conference (New York, NY)
Wednesday, June 4, 2025
Fireside Chat at 9:55 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, obesity, Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Chief Financial Officer
Jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

What is the focus of Altimmune, Inc.?

Altimmune, Inc. specializes in peptide-based therapeutics for liver and cardiometabolic diseases.

When is the H.C. Wainwright conference held?

The H.C. Wainwright 3rd Annual BioConnect conference is on May 20, 2025.

What is pemvidutide used to treat?

Pemvidutide targets MASH, obesity, Alcohol Use Disorder, and Alcohol Liver Disease.

Where can I watch the investor conference webcasts?

The webcasts can be accessed via the Events section on the Altimmune website.

Who to contact for more information about Altimmune?

For inquiries, contact Jake Robison at jake.robison@inizioevoke.com.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune investor conference pemvidutide biopharmaceutical liver disease
Last updated: May 14, 2025

Conference Timeline

Nov 11, 2025
UBS Global Healthcare Conference
8:45 AM ET • Fireside Chat
Nov 18, 2025
Jefferies Global Healthcare
11:30 AM GMT • London